FY2022 Earnings Estimate for TherapeuticsMD Inc (NASDAQ:TXMD) Issued By Oppenheimer

Share on StockTwits

TherapeuticsMD Inc (NASDAQ:TXMD) – Oppenheimer lowered their FY2022 EPS estimates for TherapeuticsMD in a note issued to investors on Tuesday, October 15th. Oppenheimer analyst J. Olson now anticipates that the company will post earnings per share of $0.20 for the year, down from their prior forecast of $0.24. Oppenheimer currently has a “Buy” rating and a $9.00 target price on the stock. Oppenheimer also issued estimates for TherapeuticsMD’s FY2023 earnings at $0.43 EPS.

A number of other equities analysts have also recently issued reports on TXMD. BidaskClub raised TherapeuticsMD from a “sell” rating to a “hold” rating in a report on Wednesday, September 11th. Zacks Investment Research raised TherapeuticsMD from a “sell” rating to a “hold” rating in a report on Saturday. Noble Financial reaffirmed a “buy” rating and issued a $13.00 target price on shares of TherapeuticsMD in a report on Friday, September 27th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $13.00 target price on shares of TherapeuticsMD in a report on Wednesday, August 7th. Finally, Jefferies Financial Group lowered their target price on TherapeuticsMD from $4.00 to $3.00 and set a “hold” rating for the company in a report on Monday, July 15th. Three analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. TherapeuticsMD has a consensus rating of “Buy” and an average target price of $10.44.

TherapeuticsMD stock opened at $3.67 on Friday. TherapeuticsMD has a 52 week low of $1.82 and a 52 week high of $6.09. The stock has a fifty day moving average of $3.49 and a 200-day moving average of $3.25. The company has a debt-to-equity ratio of 24.29, a quick ratio of 4.99 and a current ratio of 5.17. The stock has a market capitalization of $902.17 million, a P/E ratio of -6.22 and a beta of 1.69.

TherapeuticsMD (NASDAQ:TXMD) last posted its quarterly earnings results on Tuesday, August 6th. The company reported ($0.19) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.01). TherapeuticsMD had a negative return on equity of 212.57% and a negative net margin of 913.07%. The business had revenue of $6.08 million for the quarter, compared to analyst estimates of $5.12 million. During the same period last year, the firm posted ($0.15) EPS. TherapeuticsMD’s quarterly revenue was up 60.0% on a year-over-year basis.

Several hedge funds have recently modified their holdings of TXMD. Moors & Cabot Inc. acquired a new stake in shares of TherapeuticsMD in the second quarter valued at about $25,000. Moloney Securities Asset Management LLC acquired a new stake in shares of TherapeuticsMD in the second quarter valued at about $27,000. Highland Private Wealth Management acquired a new stake in shares of TherapeuticsMD in the second quarter valued at about $28,000. H D Vest Advisory Services acquired a new stake in shares of TherapeuticsMD in the second quarter valued at about $34,000. Finally, Advisor Group Inc. increased its stake in shares of TherapeuticsMD by 73.2% in the second quarter. Advisor Group Inc. now owns 13,960 shares of the company’s stock valued at $36,000 after buying an additional 5,900 shares during the period. 77.99% of the stock is owned by institutional investors.

In related news, Director Angus C. Russell purchased 10,000 shares of the firm’s stock in a transaction dated Friday, August 23rd. The stock was bought at an average price of $2.77 per share, with a total value of $27,700.00. Following the completion of the purchase, the director now owns 93,500 shares in the company, valued at approximately $258,995. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Robert G. Finizio purchased 35,000 shares of the firm’s stock in a transaction dated Tuesday, August 20th. The stock was bought at an average cost of $2.74 per share, with a total value of $95,900.00. Following the purchase, the chief executive officer now owns 18,253,964 shares of the company’s stock, valued at approximately $50,015,861.36. The disclosure for this purchase can be found here. In the last ninety days, insiders acquired 170,549 shares of company stock valued at $493,167. Insiders own 18.91% of the company’s stock.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a women's health care product company in the United States. The company's hormone therapy drug candidate is the TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil. Its preclinical projects include the development of TX-005HR, a topical progesterone cream; TX-006HR, an estradiol and progesterone topical cream to penetrate human skin; and TX-00THR and TX-0008HR, which are transdermal patch forms.

Featured Story: What is the CBOE Russell 2000® Volatility Index?

Earnings History and Estimates for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Elastos  Hits One Day Volume of $2.04 Million
Elastos Hits One Day Volume of $2.04 Million
Janney Montgomery Scott LLC Sells 16,501 Shares of Braemar Hotels & Resorts
Janney Montgomery Scott LLC Sells 16,501 Shares of Braemar Hotels & Resorts
Rhumbline Advisers Grows Stake in Westlake Chemical Co.
Rhumbline Advisers Grows Stake in Westlake Chemical Co.
Rhumbline Advisers Purchases 578 Shares of Shenandoah Telecommunications
Rhumbline Advisers Purchases 578 Shares of Shenandoah Telecommunications
Rhumbline Advisers Acquires 5,900 Shares of William Lyon Homes
Rhumbline Advisers Acquires 5,900 Shares of William Lyon Homes
Rhumbline Advisers Has $2.18 Million Holdings in Extended Stay America
Rhumbline Advisers Has $2.18 Million Holdings in Extended Stay America


 
© 2006-2019 Zolmax.